Consent to the Distribution of Changed Medicines Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act, and are set out in the Schedule hereto: Schedule Name and Strength Form Name and Address of Manufacturer Proprietary Name(if any) Salbutamol sulphate 120 g/dose equivalent to 100 g/dose salbutamol Inhaler, aerosol, metered 3M Health Care (UK) Limited, Loughborough, Leicestershire, England Airomir Autohaler Gemicitabine hydrochloride 228 mg, 1,140 mg equivalent to 200 mg, 1 g gemcitabine free base Infusion, solution Lilly Technology Center, Indianapolis, Indiana, United States of America; and Lilly France SA., Fegersheim, France Gemzar Clarithromycin 500 mg Tablet, modified release Abbott Laboratories (UK) Limited, Queensborough, Kent, England; Abbott Australasia Pty Limited, Kurnell, New South Wales, Australia; and Abbott SpA., Campoverde di Aprilia, Latina, Italy Klacid OD Mometasone furoate monohydrate 50 g/dose Spray, nasal solution Schering-Plough Laboratories NV., Heist-op-den-Berg, Belgium; and Schering-Plough Products Inc., Manati, Puerto Rico Nasonex Mometasone furoate monohydrate 50 g/dose Spray, nasal solution Schering-Plough Laboratories NV., Heist-op-den-Berg, Belgium; and Schering-Plough Products Inc., Manati, Puerto Rico Rhinax Mometasone furoate monohydrate 50 g/dose Spray, nasal solution Schering-Plough Laboratories NV., Heist-op-den-Berg, Belgium; and Schering-Plough Products Inc., Manati, Puerto Rico Uniclar Dated this 28th day of May 1999. G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.